Abstract
Background
Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin .
Objective
This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM.
Methods
The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients.
Results
Rapid clinical resolution was observed following CsA therapy.
Conclusions
We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.
Keywords
Get full access to this article
View all access options for this article.